Oncura(TM) Announces Exclusive Supply and Resale Agreement With Theragenics Corporation

CHICAGO, July 14, 2010 - ONCURA, a business unit of GE Healthcare and global leader in the
minimally invasive permanent prostate brachytherapy management of prostate
cancer, has announced that it has signed an agreement to distribute
Theragenics Corporation TheraSeed(R) palladium-103 brachytherapy seeds.

Under the terms of the agreement, Oncura will exclusively sell
the TheraSeed palladium-103 seed, subject to certain pre-existing vendor
agreements, for the treatment of prostate cancer in the U.S. and Canada. The
term of the agreement is through May 31, 2013 and provides for additional
one-year terms upon mutual agreement of the parties.

"We are pleased to re-establish our relationship with Theragenics and
offering the leading palladium seed in the industry is an important sign of
our ongoing commitment to our customers and to the continued development of
prostate brachytherapy, " said Thomas Barker, Urology Product Leader for GE
and General Manager of Oncura. "We are excited to offer our customers both
our industry standard iodine-125 based OncoSeedTM and RAPID Strand(TM)
brands, our unique ThinSeed(TM) iodine-125 products, and the leading
palladium-103 brand in TheraSeed(R)."

"We are pleased to be working with Oncura again," stated M. Christine
Jacobs, Chairman and CEO of Theragenics. "We previously supplied Oncura and
its predecessors with TheraSeed(R) from 2000 through 2005. Re-establishing
our relationship with Oncura is a testament to the quality and reliability of
Theragenics and TheraSeed(R) in the brachytherapy industry. Oncura has been a
leading brachytherapy supplier since 1991, and they bring a unique
understanding of the industry."

About Oncura

ONCURA was created in July 2003 as a joint venture of Amersham plc's
brachytherapy business. On April 8, 2004, General Electric (GE) completed its
acquisition of Amersham and in 2006 GE Healthcare acquired 100% ownership of
the Oncura Global Brachytherapy business. Oncura is a business unit of GE
Healthcare and is an acknowledged world leader in the research, development
and commercialization of brachytherapy seeds. Oncura continues to set the
benchmark in the development of innovative applications in brachytherapy in
the areas of prostate cancer, lung cancer, ocular melanoma and other solid
tumors. The manufacturing and quality assurance capabilities of GE Healthcare
combined with Oncura's knowledge and expertise in the field of Brachytherapy
uniquely place Oncura in position to further develop its global brachytherapy
business. Oncura's goal is to ensure that all cancer patients should have
access to the minimally invasive benefits of brachytherapy when it is a
suitable clinical option.

www.oncura.com

About Theragenics

Theragenics Corporation (NYSE: TGX) operates two business segments: its
surgical products business and its brachytherapy seed business. The
brachytherapy business manufactures and markets its premier product, the
palladium-103 TheraSeed(R) device (www.theraseed.com) and I-Seed, an
iodine-125 based device, which are used primarily in the minimally invasive
treatment of localized prostate cancer

www.theragenics.com

    CONTACT: Saheed Rashid
    +44-1494-737250
    saheed.rashid@ge.com
    www.oncura.com

CONTACT: Saheed Rashid, +44-1494-737250, saheed.rashid at ge.com